100 related articles for article (PubMed ID: 9127132)
21. Idiopathic hirsutism or polycystic ovary syndrome?
Jahanfar S; Eden JA
Aust N Z J Obstet Gynaecol; 1993 Nov; 33(4):414-6. PubMed ID: 8179557
[TBL] [Abstract][Full Text] [Related]
22. Focus on BMI and subclinical hypothyroidism in adolescent girls first examined for amenorrhea or oligomenorrhea. The emerging role of polycystic ovary syndrome.
Nezi M; Christopoulos P; Paltoglou G; Gryparis A; Bakoulas V; Deligeoroglou E; Creatsas G; Mastorakos G
J Pediatr Endocrinol Metab; 2016 Jun; 29(6):693-702. PubMed ID: 27089404
[TBL] [Abstract][Full Text] [Related]
23. [Different types of menstrual cycle and their significance in Chinese women diagnosed with polycystic ovary syndrome according to the Rotterdam consensus criteria].
Xu XH; Tan YC; Shi YH; Wang B; Ju XQ; Zheng QM; Hao CF; Chen ZJ
Zhonghua Yi Xue Za Zhi; 2009 Oct; 89(37):2604-6. PubMed ID: 20137675
[TBL] [Abstract][Full Text] [Related]
24. Polycystic ovaries at ultrasound: normal variant or silent polycystic ovary syndrome?
Catteau-Jonard S; Bancquart J; Poncelet E; Lefebvre-Maunoury C; Robin G; Dewailly D
Ultrasound Obstet Gynecol; 2012 Aug; 40(2):223-9. PubMed ID: 22648908
[TBL] [Abstract][Full Text] [Related]
25. The hyperprolactinemic polycystic ovary syndrome may not be an distinct entity.
Corenblum B; Taylor PJ
Fertil Steril; 1982 Nov; 38(5):549-52. PubMed ID: 6813147
[TBL] [Abstract][Full Text] [Related]
26. Endocrine features in eutestosteronemic women with polycystic ovaries.
Wada K; Imai A; Itoh T; Nishigaki-Nakagawa M; Misao R; Tamaya T
Gynecol Obstet Invest; 1994; 37(2):106-9. PubMed ID: 8150364
[TBL] [Abstract][Full Text] [Related]
27. The prevalence of polycystic ovaries in women with infertility.
Kousta E; White DM; Cela E; McCarthy MI; Franks S
Hum Reprod; 1999 Nov; 14(11):2720-3. PubMed ID: 10548608
[TBL] [Abstract][Full Text] [Related]
28. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
[TBL] [Abstract][Full Text] [Related]
29. Ovarian morphology and endocrine function in polycystic ovary syndrome.
Tena G; Moran C; Romero R; Moran S
Arch Gynecol Obstet; 2011 Dec; 284(6):1443-8. PubMed ID: 21243502
[TBL] [Abstract][Full Text] [Related]
30. [Polycystic ovary syndrome associated with remarkable hyperprolactinemia--case report].
Owecki M; Sowiński J
Pol Merkur Lekarski; 2004 Oct; 17(100):385-7. PubMed ID: 15690710
[TBL] [Abstract][Full Text] [Related]
31. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness.
Carey AH; Chan KL; Short F; White D; Williamson R; Franks S
Clin Endocrinol (Oxf); 1993 Jun; 38(6):653-8. PubMed ID: 8334753
[TBL] [Abstract][Full Text] [Related]
32. Increased anti-Mullerian hormone levels and ovarian size in a subgroup of women with functional hypothalamic amenorrhea: further identification of the link between polycystic ovary syndrome and functional hypothalamic amenorrhea.
Carmina E; Fruzzetti F; Lobo RA
Am J Obstet Gynecol; 2016 Jun; 214(6):714.e1-6. PubMed ID: 26767792
[TBL] [Abstract][Full Text] [Related]
33. The benefits of finasteride for hirsute women with polycystic ovary syndrome or idiopathic hirsutism.
Lakryc EM; Motta EL; Soares JM; Haidar MA; de Lima GR; Baracat EC
Gynecol Endocrinol; 2003 Feb; 17(1):57-63. PubMed ID: 12724020
[TBL] [Abstract][Full Text] [Related]
34. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
35. Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.
Piouka A; Farmakiotis D; Katsikis I; Macut D; Gerou S; Panidis D
Am J Physiol Endocrinol Metab; 2009 Feb; 296(2):E238-43. PubMed ID: 18957615
[TBL] [Abstract][Full Text] [Related]
36. Features of Turner's syndrome in women with polycystic ovaries.
Givens JR; Wilroy RS; Summitt RL; Andersen RN; Wiser WL; Fish SA
Obstet Gynecol; 1975 Jun; 45(6):619-24. PubMed ID: 1143721
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus.
Kelestimur F; Unluhizarci K; Baybuga H; Atmaca H; Bayram F; Sahin Y
Fertil Steril; 2006 Aug; 86(2):405-10. PubMed ID: 16762349
[TBL] [Abstract][Full Text] [Related]
38. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
Hassa H; Tanir HM; Yildiz Z
Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome.
Falaschi P; Rocco A; del Pozo E
J Clin Endocrinol Metab; 1986 Feb; 62(2):348-51. PubMed ID: 3510225
[TBL] [Abstract][Full Text] [Related]
40. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
Prelević GM; Würzburger MI; Perić LA
J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
